Reddy博士有权将Immutep的癌症药物在关键市场外出售, Dr Reddy’s gains rights to sell Immutep’s cancer drug outside key markets in deal up to $349.5M.

Reddy博士的实验室已经获得了在北美、欧洲、日本和大中国以外的地区开发和商业化Immmutep癌症药物白化藻类的专有权利,这笔交易价值高达3.495亿美元,具有潜在的里程碑意义。 Dr Reddy’s Laboratories has secured exclusive rights to develop and commercialize Immutep’s cancer drug eftilagimod alfa in regions outside North America, Europe, Japan, and Greater China under a deal worth up to $349.5 million in potential milestones. 印度公司将支付预付的2 000万美元,销售使用两位数的版税,而Immutep公司则保留关键市场的制造业和商业权利。 The Indian company will pay an upfront $20 million, with double-digit royalties on sales, while Immutep retains manufacturing and commercial rights in key markets. 该药物目前正在对非小细胞肺癌进行第三阶段试验,并正在研究其他癌症,其目的是提高免疫疗法的效力。 The drug, currently in a Phase III trial for non-small cell lung cancer and being studied for other cancers, aims to enhance immunotherapy effectiveness. 该伙伴关系标志着Reddy博士在全球肿瘤学方面的战略扩张。 The partnership marks a strategic expansion for Dr Reddy’s in global oncology.